Login / Signup

Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.

Miquel BlascoAlexandra Martínez-RocaLuis G Rodríguez-LobatoAdriana Garcia-HerreraLaura RosinolPedro CastroSara FernándezLuis F QuintanaMaría T CibeiraJoan BladéCarlos Fernández de LarreaNatalia TovarRaquel JimenezEsteban PochElena GuillenJosep M CampistolEnric CarrerasMaribel Díaz-RicartMarta Palomo
Published in: British journal of haematology (2020)
Carfilzomib has been associated with the development of thrombotic microangiopathy (TMA) in relapsed/refractory multiple myeloma patients, a severe disease with no currently available aetiological treatment. We evaluated the potential role of terminal complement pathway in four patients with carfilzomib-induced TMA. Membrane attack complex (C5b-9) deposition on endothelial cells in culture exposed to plasma from patients during the acute phase of the disease suggests complement overactivation as a mechanism of potential endothelial damage in three out of four patients. If confirmed in larger cohorts, C5b-9 evaluation will allow early identification of patients who could benefit from complement blockade and treatment monitoring.
Keyphrases